Imipenem

What the laboratory says this test is for

Rapidly growing mycobacteria and Nocardia/aerobic actinomycetes can cause a variety of serious infections, particularly in immunocompromised patients. Resistance, toxicity, intolerance, and therapeutic failures may occur with traditional empiric treatment with drugs of choice. Antimicrobial susceptibility testing, especially with newer agents, may help to guide appropriate therapeutic choices.

What the laboratory says this test is for

Resistance of anaerobic organisms to antibiotics has been increasing in recent years. Significant increases in resistance are now seen with non-Bacteroides fragilis group gram-negatives and other genera such as Clostridium, Fusobacterium, Prevotella, and Peptostreptococcus. Since negative therapeutic outcomes are directly associated with antimicrobial resistance, accurate, timely susceptibility testing of anaerobes has become more important.

What the laboratory says this test is for

The role of rapidly growing Mycobacteria, especially M. fortuitum and M. chelonae, as agents of human disease has become more clearly established in modern times. Primary antitubercular drugs generally are not effective in the treatment of these organisms. Therapy had shifted to the use of antimicrobial agents routinely used to treat other bacterial infections.